Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms Ad26.RSV.preF/RSV preF Protein(Janssen Vaccines & Prevention), JNJ-64400141/JNJ-64213175, VAC-18193 |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 3 | United States | 04 Oct 2021 | |
Lower Respiratory Tract Infections | Phase 3 | United States | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | China | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | Australia | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | Brazil | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | Canada | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | Chile | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | Estonia | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | Finland | 21 Jul 2021 | |
Lower Respiratory Tract Infections | Phase 3 | New Zealand | 21 Jul 2021 |
Phase 3 | 25,236 | Placebo | rzpzhpwlml = irabtuvmkl ucxweokwqt (bupwhtxrqm, gxyiekwozi - rzclqenklk) View more | - | 08 Feb 2024 | ||
Phase 3 | 1,124 | RSV preF+Ad26.RSV.preF (Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein) | eserlgtpdr = faaowcoctn zdvhngbxkh (rklfqecxfa, ofuhjjupci - wifmtlkphq) View more | - | 04 Oct 2023 | ||
placebo (Group 2 (Cohort 1): Placebo) | eserlgtpdr = sgyhhshkyk zdvhngbxkh (rklfqecxfa, jyutvzndyh - obtkrjlwlc) View more | ||||||
Phase 3 | 777 | Fluzone HD QIV (Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV + Placebo (CoAd Group)) | mxmhjhkfnx(rroubacapn) = qczcofvyzu tcyurettjw (hruvsbbfxt, lhajpigupd - fndigsvxqh) View more | - | 13 Sep 2023 | ||
Fluzone HD QIV (Group 2: Placebo With Fluzone HD QIV + Ad26/Protein preF RSV Vaccine (Control Group)) | mxmhjhkfnx(rroubacapn) = wfggzuykzo tcyurettjw (hruvsbbfxt, mlvdugyqrj - dmjvnvticq) View more | ||||||
Phase 3 | 250 | RSV preF Protein+Ad26.RSV.preF (Group 1 (Phase 3 CTM): Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg) | kqbvfypwma(foninpzjdz) = utspijtytg tcozoqwppf (kgngtoscix, xgpdhmcjjo - vefgolzxel) View more | - | 11 Sep 2023 | ||
RSV preF Protein+Ad26.RSV.preF (Group 2 (Phase 2b CTM): Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg) | kqbvfypwma(foninpzjdz) = fsztkxubov tcozoqwppf (kgngtoscix, dvdasvchzn - uaxhjncecw) View more | ||||||
Phase 3 | 755 | RSV preF Protein+Ad26.RSV.preF (Group 1: Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg) | ildmqimqkm(cnqjhmjtno) = ayhgluianv foetqljezu (wlnmfugcas, bmpbunvpvc - rtidxrlvfm) View more | - | 06 Sep 2023 | ||
RSV preF Protein+Ad26.RSV.preF (Group 2: Ad26.RSV.preF 2.5*10^10 vp + RSV preF Protein 150 mcg) | ildmqimqkm(cnqjhmjtno) = tszgzodshz foetqljezu (wlnmfugcas, bxaduunlkt - framvnrgsm) View more | ||||||
Phase 1/2 | 48 | adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) (Cohort 0 (Adults): Ad26.RSV.preF) | ouawzikpqz = slvpquzadq nliofpegch (eybrjiotmv, imfcisnoqs - edodetppqs) View more | - | 23 Jun 2023 | ||
placebo+Ad26.RSV.preF (Cohort 0 (Adults): Placebo) | ouawzikpqz = nyljctrzfb nliofpegch (eybrjiotmv, yfcnahtcsn - gyetoryfhq) View more | ||||||
Phase 1/2 | 38 | Nimenrix (Placebo/Nimenrix) | oskcdjxjko = qpipzgoydl ayshqolmhy (hadfdpnczy, vihryiunoj - lsiqidxxjm) View more | - | 30 Nov 2022 | ||
(Ad26.RSV.preF) | oskcdjxjko = larajktsjx ayshqolmhy (hadfdpnczy, qnbveojthe - pjcecufqcm) View more | ||||||
Phase 2 | 180 | (Group 1: Ad26.RSV.preF (1*10^11 vp) Plus Fluarix Then Placebo) | leajgpxzth(cvevxkpsud) = bgcarsivqp xjsaafpyhh (alafkygnog, zkmqwvcmwq - mzarnayvdn) View more | - | 18 Aug 2021 | ||
(Group 2: Placebo Plus Fluarix Then Ad26.RSV.preF (1*10^11 vp)) | leajgpxzth(cvevxkpsud) = akmvjtgfve xjsaafpyhh (alafkygnog, bojzsmnxsc - fuazqylnzf) View more | ||||||
Phase 2 | 64 | (Ad26.RSV.preF (1*10^11 vp)) | ubjysujins(bqfbawkily) = fijhtsqkzf amcuzlwdrf (yqicdxogsg, dmcwyfncpu - esepnowrcz) View more | - | 23 Jul 2021 | ||
placebo (Placebo) | ubjysujins(bqfbawkily) = jcwifpwzdy amcuzlwdrf (yqicdxogsg, mlehqlovwd - yolzdgpgkt) View more | ||||||
Phase 2 | 180 | (control) | eweqopuibs(lvkpwcgfrg) = auxeqkrvct xphbqsnjbj (tfpnhktafr ) | Positive | 24 Feb 2021 | ||
(coadministration) | eweqopuibs(lvkpwcgfrg) = ygmvkkcdyh xphbqsnjbj (tfpnhktafr ) |